MGHD 2018

Background: Outcomes in acute lymphoblastic leukaemia (ALL) in low income countries are poor, with only 20-50% of patients successfully treated. Many of the failures are due to relapsed disease but mortality from complications of therapy is also increased. Hunger et al. have proposed regimens of graduated intensity for ALL in resource-limited centres so that capacity for managing toxicity, particularly neutropenic fever can be built over time without excessive treatment-related deaths (Hunger, Sung, & Howard, 2009). The Butaro Cancer Center of Excellence (BCCOE) is located in a Rwandan district hospital with limited antibiotics, no microbiology and no intensive care. The centre began treating ALL in 2012 with the Hunger 1 regimen; few deaths from toxicity were experienced but the cure rate was unacceptably low (Rubagumya, Xu, et al., 2017). In October 2016 the centre transitioned to using the Hunger 2 regimen, which is more intense and incorporates a delayed intensification phase. Objective: The objective was to assess the toxicity and interim outcomes at 24 weeks of the first 25 patients treated with the Hunger 2 regimen for ALL at BCCOE in Rwanda starting from October 2016. Methods: The sample included all patients, both adult and paediatric, with a pathology-confirmed diagnosis of ALL, from October 2016 to September 2017, who were treated with the Hunger 2 regimen. Patients who received previous treatment with chemotherapy were excluded. A retrospective cohort study design was used, with patient status at week 24 as the key outcome variable, as well as survival of episodes of neutropenic fever. Routine data was collected by manual chart review. Results: Twenty-four patients had a bone marrow diagnosis of ALL during the study period, but only 17 of those survived to start treatment with the Hunger 2 regimen. The cohort included a high Page 7 of 41 proportion of patients with high-risk features such as older age, T-cell subtype and white blood count (WBC) greater than 50,000 at presentation. Most treatment delays were caused by neutropenia and thrombocytopenia, with negligible delays due to medication stockouts or social factors. There was a high use of red blood cell and platelet transfusions during the induction phase. Patients had a median of one episode of neutropenic fever. Median time to antibiotics was 10.5 hours. Identified infections included malaria, pyoderma, pneumonia and enterocolitis.. The most common antibiotics used were ceftriaxone and ceftazidime. All episodes resolved with no patient deaths. The majority of patients (63%) who commenced treatment achieved remission and were still alive and in treatment at week 24. Two patients failed induction, one patient died during induction, another patient abandoned treatment and another transferred out. Conclusion: This study suggests that neutropenic fever may be less of a limiting factor in ALL treatment in resource-poor settings than has been supposed, as all patients survived this complication despite limited resources. The high number of deaths prior to treatment was surprising; this may be due to delayed presentation but deserves further study. The ability to report on ultimate outcomes of the treatment and associations with risk factors was limited by the short duration of follow-up and small cohort size.